CVRx (CVRX) Expected to Release Quarterly Earnings on Thursday

CVRx (NASDAQ:CVRX) is expected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect CVRx to announce earnings of ($0.49) per share and revenue of $13.93 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

CVRx (NASDAQ:CVRX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.01). CVRx had a negative net margin of 84.93% and a negative return on equity of 152.35%. The firm had revenue of $15.71 million for the quarter, compared to analyst estimates of $15.55 million. On average, analysts expect CVRx to post ($2.00) EPS for the current fiscal year and ($1.91) EPS for the next fiscal year.

CVRx Stock Up 0.7%

CVRX stock opened at $1.38 on Wednesday. The company has a quick ratio of 6.87, a current ratio of 8.04 and a debt-to-equity ratio of 2.94. CVRx has a fifty-two week low of $1.25 and a fifty-two week high of $10.63. The firm’s 50-day simple moving average is $2.20 and its 200 day simple moving average is $5.22. The stock has a market cap of $36.76 million, a PE ratio of -0.70 and a beta of 0.81.

Analysts Set New Price Targets

CVRX has been the topic of several analyst reports. Cantor Fitzgerald dropped their price target on shares of CVRx from $13.00 to $5.00 and set an “overweight” rating on the stock in a research note on Monday, August 17th. Wall Street Zen raised CVRx from a “sell” rating to a “hold” rating in a report on Saturday, October 10th. Canaccord Genuity Group set a $5.00 price objective on CVRx in a research report on Tuesday, September 22nd. Craig Hallum downgraded CVRx from a “buy” rating to a “hold” rating and set a $4.00 price objective for the company. in a research report on Friday, August 7th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of CVRx in a report on Friday. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, CVRx presently has a consensus rating of “Hold” and a consensus target price of $4.30.

Insider Buying and Selling at CVRx

In related news, COO Brent Binkowski acquired 26,223 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was acquired at an average cost of $2.91 per share, for a total transaction of $76,308.93. Following the completion of the acquisition, the chief operating officer directly owned 56,514 shares of the company’s stock, valued at approximately $164,455.74. The trade was a 86.57% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 16.60% of the company’s stock.

About CVRx

CVRx, Inc (NASDAQ: CVRX) is a medical device company focused on developing and commercializing neuromodulation therapies for patients with cardiovascular diseases. The company’s technology is designed to activate the body’s natural nervous system pathways to help regulate cardiovascular function.

CVRx’s primary product is the Barostim system, an implantable device that delivers electrical stimulation to baroreceptors located near the carotid arteries. By influencing signals between the cardiovascular system and the brain, Barostim is intended to reduce excessive sympathetic nervous system activity and improve symptoms and function in certain patients with heart failure.